Skip to main content

Cocaine Dependence

4
Pipeline Programs
5
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
Buprenorphine + NaltrexonePhase 2/31 trial
Active Trials
NCT01402492Completed302Est. Mar 2013
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
3 programs
2
1
Clavulanic Acid Only ProductPhase 21 trial
Clavulanic AcidPhase 11 trial
Clavulanic acidPhase 11 trial
Active Trials
NCT04411914Completed13Est. Mar 2022
NCT02563769Completed10Est. May 2018
NCT05562349Unknown65Est. Jul 2024
Catalyst Pharmaceuticals
Catalyst PharmaceuticalsCORAL GABLES, FL
2 programs
VigabatrinPHASE_21 trial
vigabatrinPHASE_21 trial
Active Trials
NCT00527683Completed100Est. Nov 2007
NCT00611130Completed186Est. Oct 2012
Alliance Pharmaceuticals
1 program
cocaineN/A1 trial
Active Trials
NCT00451230Completed15Est. Jun 2005
Sound Pharmaceuticals
1 program
quetiapine fumarateN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angeles TherapeuticsBuprenorphine + Naltrexone
Temple TherapeuticsClavulanic Acid Only Product
Catalyst Pharmaceuticalsvigabatrin
Catalyst PharmaceuticalsVigabatrin
Temple TherapeuticsClavulanic Acid
Temple TherapeuticsClavulanic acid
Alliance Pharmaceuticalscocaine

Clinical Trials (7)

Total enrollment: 691 patients across 7 trials

NCT01402492Angeles TherapeuticsBuprenorphine + Naltrexone

Cocaine Use Reduction With Buprenorphine

Start: Sep 2011Est. completion: Mar 2013302 patients
Phase 2/3Completed
NCT05562349Temple TherapeuticsClavulanic Acid Only Product

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Start: May 2023Est. completion: Jul 202465 patients
Phase 2Unknown
NCT00611130Catalyst Pharmaceuticalsvigabatrin

Vigabatrin for Treatment of Cocaine Dependence

Start: Jan 2008Est. completion: Oct 2012186 patients
Phase 2Completed
NCT00527683Catalyst PharmaceuticalsVigabatrin

Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence

Start: Apr 2007Est. completion: Nov 2007100 patients
Phase 2Completed
NCT04411914Temple TherapeuticsClavulanic Acid

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

Start: Sep 2020Est. completion: Mar 202213 patients
Phase 1Completed
NCT02563769Temple TherapeuticsClavulanic acid

Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study

Start: Oct 2016Est. completion: May 201810 patients
Phase 1Completed
NCT00451230Alliance Pharmaceuticalscocaine

Metabolic Effects of Cocaine

Start: Jun 2005Est. completion: Jun 200515 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.